THY-Tau22 | ALZFORUM
Troquier L, Caillierez M, Burnouf S, Fernandez-Gomez FJ, Grosjean MJ, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012 Jan …
Tau protein isoforms, phosphorylation and role in ... - ALZFORUM
Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR.Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.
RG7345 - ALZFORUM
Nov 20, 2015 · Troquier L, Caillierez M, Burnouf S, Fernandez-Gomez FJ, Grosjean MJ, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012 Jan 23; PubMed.
NLRP3 inflammasome activation drives tau pathology. - ALZFORUM
Nov 29, 2019 · View all comments by Hugh Perry; Dave Morgan Michigan State University; Posted: 26 Nov 2019 News: Microglia Inflammasome Stokes Tau Phosphorylation, Tangles
Neurotrophic factors in Alzheimer's disease: role of axonal …
Schindowski K, Belarbi K, Buée L.Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 2008 Feb;7 Suppl 1:43-56.
Clinical value of plasma ALZpath pTau217 immunoassay for
Apr 30, 2024 · Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Buee L, Blanc F, Paquet C, Allinquant B, Bombois S, Gabelle A, Hanon O, BALTAZAR study group. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2024 Oct 16;95(11):1046-1053. PubMed. Recommends
Aggregate-selective removal of pathological tau by clustering …
Sep 20, 2024 · Benn J, Cheng S, Keeling S, Smith AE, Vaysburd MJ, Böken D, Miller LV, Katsinelos T, Franco C, Dupré E, Danis C, Landrieu I, Buée L, Klenerman D, James LC, McEwan WA.
NETWORKING FOR A CURE - ALZFORUM
Sep 6, 2022 · Education MSc @ Univ Lille, France. PhD benchwork in New York (MSMC 1989-1992) and graduate in 1992 in Lille, France
New Arrows Aimed at Tau: Single-Domain Antibody, Peptibody, …
03 May 2023. Tau pathology is proving a tough nut to crack, with most antibodies directed against it posting negative results in clinical trials thus far.
To Block Tau’s Proteopathic Spread, Antibody Must Attack
The French researchers injected pathological tau from AD brain into the hippocampi of young tau transgenic mice to trigger pathology. This was followed by six weekly intraperitoneal tau antibody injections. In Turin, Morvane Colin in Buee’s group said that a mouse version of UCB0107 prevented tau aggregates from forming.